All In Biotech

Drug Trial Radar · NCT07570069

Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

A Phase 1, Open-label Drug-drug Interaction Study to Evaluate the Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

May 7, 2026

Primary completion

Jul 16, 2026

Study completion Jul 16, 2026

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of efavirenz.

Conditions

  • Pain

Interventions

  • SuzetrigineDrug

    Tablet for oral administration.

  • EfavirenzDrug

    Tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of SUZ and its Metabolite in the Absence and Presence of EfavirenzTime frame: Day 15 and Day 30
  2. Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCτ) of SUZ and its Metabolite in the Absence and Presence of EfavirenzTime frame: Day 15 and Day 30

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON - Utah - Salt Lake City Office

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.